Real-World Immune Globulin Subcutaneous 16.5% Use in Treatment-Naïve Patients with Primary Immunodeficiency

Presented at IgNS 2022

Authors:
Lucinda J. Van Anglen, PharmD
Jeffrey W. Langford, MD, AE-C
Richard F. Herrscher, MD, FACAAI
Dawn N. Kim-Romo, PharmD, PhD, MS